<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lexaria Bioscience Corp — News on 6ix</title>
<link>https://6ix.com/company/lexaria-bioscience-corp</link>
<description>Latest news and press releases for Lexaria Bioscience Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lexaria-bioscience-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683590b178dffbe2df102249.webp</url>
<title>Lexaria Bioscience Corp</title>
<link>https://6ix.com/company/lexaria-bioscience-corp</link>
</image>
<item>
<title>Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-launches-new-study-to-examine-next-generation-glp-1-drugs</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-launches-new-study-to-examine-next-generation-glp-1-drugs</guid>
<pubDate>Thu, 23 Apr 2026 04:00:00 GMT</pubDate>
<description>Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire /</description>
</item>
<item>
<title>Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexarias-new-animal-study-aims-to-expand-valuable-intellectual-property</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexarias-new-animal-study-aims-to-expand-valuable-intellectual-property</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Contracts Signed for Animal Study GLP-1-A26-1 KELOWNA, BRITISH COLUMBIA - April 15, 2026 (NEWMEDIAWIRE) - Lexaria Bioscience Corp. (Nasdaq: LEXX), (the</description>
</item>
<item>
<title>Lexaria to Begin New Human Clinical Study in GLP-1</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-to-begin-new-human-clinical-study-in-glp-1-4</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-to-begin-new-human-clinical-study-in-glp-1-4</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Contracts signed for Human Pilot Study #7 (GLP-1-H26-7) KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company"</description>
</item>
<item>
<title>Lexaria Announces New R&D Plans for 2026</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-announces-new-randd-plans-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-announces-new-randd-plans-for-2026</guid>
<pubDate>Wed, 04 Mar 2026 14:25:00 GMT</pubDate>
<description>Exciting new human and animal studies designed to enhance business opportunities KELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces ...</description>
</item>
<item>
<title>Lexaria Announces Positive Final Results From Human Pilot Study #5</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-announces-positive-final-results-141500411</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-announces-positive-final-results-141500411</guid>
<pubDate>Thu, 05 Feb 2026 14:15:00 GMT</pubDate>
<description>Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms ...</description>
</item>
<item>
<title>Lexaria Awarded Six Additional Patents</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-awarded-six-additional-patents-142000660</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-awarded-six-additional-patents-142000660</guid>
<pubDate>Thu, 22 Jan 2026 14:20:00 GMT</pubDate>
<description>Lexaria now has 60 patents granted around much of the world Lexaria urges shareholders to vote at upcoming 2026 Annual Meeting KELOWNA, BC / ACCESS Newswire / January 22, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), ...</description>
</item>
<item>
<title>Lexaria Releases Annual Letter from the CEO</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-releases-annual-letter-ceo-141000257</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-releases-annual-letter-ceo-141000257</guid>
<pubDate>Mon, 12 Jan 2026 14:10:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive ...</description>
</item>
<item>
<title>Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-releases-additional-results-successful-142000864</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-releases-additional-results-successful-142000864</guid>
<pubDate>Tue, 30 Dec 2025 14:20:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint ...</description>
</item>
<item>
<title>Lexaria Releases Additional Results From Its Successful Phase 1b Study GLP-1-H24-4</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-releases-additional-results-from-its-successful-phase-1b-study-glp-1-h24-4</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-releases-additional-results-from-its-successful-phase-1b-study-glp-1-h24-4</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>KELOWNA, BRITISH COLUMBIA - December 30, 2025 (NEWMEDIAWIRE) - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator</description>
</item>
<item>
<title>Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/primary-endpoint-successfully-achieved-lexarias-142900347</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/primary-endpoint-successfully-achieved-lexarias-142900347</guid>
<pubDate>Tue, 23 Dec 2025 14:29:00 GMT</pubDate>
<description>DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings create runway for prospective new 2026 development ...</description>
</item>
<item>
<title>Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-closing-210000239</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-closing-210000239</guid>
<pubDate>Tue, 16 Dec 2025 21:00:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / December 16, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct ...</description>
</item>
<item>
<title>Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-3-130000937</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-3-130000937</guid>
<pubDate>Mon, 15 Dec 2025 13:00:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / December 15, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the ...</description>
</item>
<item>
<title>Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/material-transfer-agreement-between-pharmaceutical-141000107</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/material-transfer-agreement-between-pharmaceutical-141000107</guid>
<pubDate>Wed, 12 Nov 2025 14:10:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / November 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally ...</description>
</item>
<item>
<title>Lexaria Bioscience Corp. Provides Strategic Update</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-provides-strategic-132000365</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-provides-strategic-132000365</guid>
<pubDate>Thu, 09 Oct 2025 13:20:00 GMT</pubDate>
<description>Strategic Business Development Advisory Firm Engaged To Support New Business Development Activities Lexaria Awarded 4 New Patents KELOWNA, BC / ACCESS Newswire / October 9, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" ...</description>
</item>
<item>
<title>Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-closing-203000260</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-closing-203000260</guid>
<pubDate>Mon, 29 Sep 2025 20:30:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / September 29, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered ...</description>
</item>
<item>
<title>Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-4-120000037</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-bioscience-corp-announces-4-120000037</guid>
<pubDate>Fri, 26 Sep 2025 12:00:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / September 26, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the ...</description>
</item>
<item>
<title>Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexarias-technology-supports-higher-levels-152000343</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexarias-technology-supports-higher-levels-152000343</guid>
<pubDate>Fri, 19 Sep 2025 15:20:00 GMT</pubDate>
<description>Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy KELOWNA, BC / ACCESS Newswire / September 19, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator ...</description>
</item>
<item>
<title>Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-attending-27th-annual-h-132000265</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexaria-attending-27th-annual-h-132000265</guid>
<pubDate>Wed, 27 Aug 2025 13:20:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it will participate in the 27th Annual H.C. Wainwright ...</description>
</item>
<item>
<title>Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/lexarias-phase-1b-glp-1-132000183</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/lexarias-phase-1b-glp-1-132000183</guid>
<pubDate>Thu, 14 Aug 2025 13:20:00 GMT</pubDate>
<description>KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") ...</description>
</item>
<item>
<title>GLP-1 "Arms Race" Broadens to Include Dozens of Companies</title>
<link>https://6ix.com/company/lexaria-bioscience-corp/news/glp-1-arms-race-broadens-132000731</link>
<guid isPermaLink="true">https://6ix.com/company/lexaria-bioscience-corp/news/glp-1-arms-race-broadens-132000731</guid>
<pubDate>Wed, 06 Aug 2025 13:20:00 GMT</pubDate>
<description>Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, ...</description>
</item>
</channel>
</rss>